Taranabant Loss No Surprise For Obesity Field, But Shock To Merck’s Pipeline
Executive Summary
Merck's widely expected decision to drop its Phase III obesity candidate taranabant places further doubt on the tainted cannabinoid-1 receptor antagonist class, but it also places doubt on Merck's near-term pipeline
You may also be interested in...
Pharma and Academia: Finding New Ways to Join Hands for Mutual Benefit
As Big Pharmas seek to hedge their development risk and look for more externally sourced programs, partnerships with academic institutions are one of the many ingredients in the R&D secret sauce. Such deals aren't the academic-industry tie-ups of yore-where Big Pharma sought small money partnerships without giving a lot back to their academic partners. Business development execs view them as yet another way to access critically important innovation.
How To Have A Winning R&D Strategy In Trying Times: An Interview With Merck Research Labs’ Gary Herman
Merck's 'fail fast' attitude toward R&D not only "more than pays for itself," it's "going to open up opportunities for us to do a lot more with our investment," Herman said.
Merck’s Heart Failure Drug Flunks Phase III
Rolofylline fails to meet primary and secondary endpoints in a Phase III trial.